Recro Pharma, Inc. (REPH)
Price:
2.09 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Intra-Cellular Therapies, Inc.
VALUE SCORE:
0
2nd position
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
11
The best
Lantheus Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
NEWS
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-01 19:33:06Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
globenewswire.com
2022-02-22 16:05:00Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
globenewswire.com
2022-01-03 07:00:00SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
zacks.com
2021-12-08 10:36:22Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-10 02:20:30Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
benzinga.com
2021-10-20 15:07:17Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.
Recro Reports Inducement Grants For New Staff
globenewswire.com
2021-10-06 07:00:00Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-10-01 10:09:33Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
zacks.com
2021-09-16 13:44:06Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
globenewswire.com
2021-08-17 07:00:00Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
globenewswire.com
2021-08-13 08:50:00Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms
Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-08-09 18:23:11Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript
Recro Pharma: Q2 Earnings Insights
benzinga.com
2021-08-09 17:05:54Shares of Recro Pharma (NASDAQ:REPH) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 112.00% over the past year to $0.03, which beat the estimate of ($0.11).
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
globenewswire.com
2021-08-02 16:05:00Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern
Recro Appoints Laura L. Parks, Ph.D.
globenewswire.com
2021-06-16 07:00:00Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com
2021-05-14 09:15:00Underwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million
No data to display
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-01 19:33:06Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
globenewswire.com
2022-02-22 16:05:00Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
globenewswire.com
2022-01-03 07:00:00SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
zacks.com
2021-12-08 10:36:22Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-10 02:20:30Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
benzinga.com
2021-10-20 15:07:17Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.
Recro Reports Inducement Grants For New Staff
globenewswire.com
2021-10-06 07:00:00Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-10-01 10:09:33Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
zacks.com
2021-09-16 13:44:06Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
globenewswire.com
2021-08-17 07:00:00Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
globenewswire.com
2021-08-13 08:50:00Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms
Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-08-09 18:23:11Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript
Recro Pharma: Q2 Earnings Insights
benzinga.com
2021-08-09 17:05:54Shares of Recro Pharma (NASDAQ:REPH) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 112.00% over the past year to $0.03, which beat the estimate of ($0.11).
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
globenewswire.com
2021-08-02 16:05:00Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern
Recro Appoints Laura L. Parks, Ph.D.
globenewswire.com
2021-06-16 07:00:00Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com
2021-05-14 09:15:00Underwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million